secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2024-09-17T23:59:59+00:00
Accession:  0001104659-24-100714
Event type: litigation
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics files new cross-claims in FDA suit challenging YUTREPIA NDA acceptance
--------------------------------------------------------------------------------

- On Sept. 16, 2024, United Therapeutics filed new cross-claims against FDA in the existing FDA Suit.
- Cross-claims re-assert challenge to FDA's acceptance of Liquidia's NDA for YUTREPIA (treprostinil).
- Liquidia states it will vigorously defend its ability to launch YUTREPIA and against the allegations.
- United had voluntarily dismissed a similar challenge on Aug. 20, 2024, before refiling as cross-claims.
- Liquidia's prior suit challenging FDA's 3-year NCI exclusivity for Tyvaso DPI remains ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924100714/0001104659-24-100714-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465924100714/tm2424262d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-100714

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer